



CLINICAL GUIDELINE

Mycoplasma Genitalium

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Version Number:	2
Does this version include changes to clinical advice:	No
Date Approved:	27 th March 2026
Date of Next Review:	31 st March 2027
Lead Author:	Kay McAllister
Approval Group:	Sandyford Governance Group
Guideline ID number:	1251

Important Note:

The online version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

MYCOPLASMA GENITALIUM

Key points:

- Testing is restricted to specific clinical presentations.
- MHRA caution about fluoroquinolones requires clear documentation of fully informed discussion and decision making prior to prescribing
- Management of cases of treatment failure updated
- Test of cure is recommended only for people who remain symptomatic after treatment

Summary

M genitalium is now recognized as a significant cause of male urethritis, and has a probable role in pelvic infection, cervicitis and possibly proctitis. However most people infected will come to no harm, and screening and testing people who have no symptoms is not helpful.

In Sandyford we only test people for particular reasons. Testing is not available in GP or acute settings.

We use molecular resistance tests to guide sequential antibiotic choice. There is a high level of resistance to macrolides so antibiotic selection and careful stewardship is critical. Moxifloxacin has a risk of serious side-effects, with strengthened warnings about fluoroquinolone use published by MHRA in January 2024 . Recent guideline updates in USA, Europe and Australia have reduced course length to 7 days.

We only test ongoing sexual partners (no look-backs) and prefer to await their own results before considering treatment

Diagnosis

Test for *M.genitalium* only in the following situations.

- **Proven** non-gonococcal urethritis (*tests organized by the Sandyford lab staff*)
- First return for microscopy proven, **persistent or recurrent NGU** where testing for *M.genitalium* has not been done
- Signs and symptoms suggestive of **pelvic inflammatory disease**
- **Persistent symptoms of epididymo-orchitis, mucopurulent cervicitis or proctitis** after other infections have been ruled out and index of suspicion is high
- **Current ongoing contacts** of *M. genitalium* (NB NOT past contacts)
- **Test of cure – only if indicated (see below)**

How to Test:

Male anatomy

- First void urine (pipette into Abbott sample tube)
 - If urethritis suspected DO NOT request on NaSH. Leave sample in the '**Box C: Samples for M. gen. testing**' and the biomedical scientist will add the test on if urethritis confirmed – see flow chart

Female anatomy

- Vulvo-vaginal swab (self-taken or clinician-taken) into Abbott sample tube

Other anatomical sites

- Rectal testing indicated if
 - (i) site is likely risk of reinfection to a known index case.
 - (ii) Second-line investigation of proctitis where no other cause can be found.

No throat testing is required

Transgender men, non binary (AFAB) post gender reassignment surgery (GRS):

- Little data means no firm recommendations. Specimen type should be guided by sexual history and symptoms

Window period:

Unfortunately there are no data on the incubation period for *M genitalium*, nor on the likely window period before a laboratory test becomes reliably positive. However, it is likely that sensitive tests will detect early infection, two weeks seems clinically reasonable.

Laboratory Issues:

- From Jun 2021 *M. genitalium* testing happens at the West of Scotland virus lab on residual sample from the Abbott Ct/NG NAAT test where this has been taken.
- You do **not** need to send two samples if testing for Ct/GC is required as well
- In the case of **urethritis** *M. genitalium* testing will be added on from the Sandyford lab **after microscopy confirmation** both Central and the hubs. It helps if urines for where this may be required are placed in the separate collection box. The biomedical scientist will add a note in the microscopy form to show they have done this.

The screenshot displays the Sandyford ELMIS system interface. The patient is identified as DUNDEE, Croc 3, born 21-Apr-1996 (25y), with sex 'Other Specific' and NaSH Number AN01183575. The form is titled 'Special Forms' and is for a 'Microscopy' test requested on 19/05/2021. The test was performed by Mark Mason. The results are as follows:

Site	WBC	GNDG	Yeasts	Vag Flora	Wet Prep
Urethral	+++ (±10)	Not seen			
Cervical					
Vaginal					
AV Score	Score	Description			
Rectal					
Sub-prepuce					
Vault					
Anatomical Site	Dark Ground	Result			

Comments: Specimen sent for M gen testing.

Microscopy form showing NGU and that M gen testing has been ordered.

- For **other indications** send Abbott tube (orange top) and request on SunQuest ICE
- Turnround times can be up to 7 days
- All *M genitalium* samples are tested locally for macrolide resistance sequence as part of the diagnostic test Positive samples are automatically sent on to the Edinburgh reference laboratory for sequencing.

Flow Chart (i) (for Sandyford Central)

MALE ANATOMY PATIENTS

Patient with suspected NGU/GC, recurrent NGU or epididymo-orchitis



Collect FVU and obtain urethral microscopy slide



Clinician orders Ct & Gc on Sunquest and sticks Sunquest label on sample



Specimen taken to BOX C (**samples for M.gen testing**)
(Ground floor specimen collection room)




BOX C specimens are transferred to Sandyford laboratory M.gen tray



Sandyford Laboratory BMS :

BMS performs microscopy and if NGU/GC confirmed, locate specimen from M.gen tray and add red sticker (WoSSVC Mycoplasma Testing) to the specimen bag



Sandyford Clinician :

Clinician checks microscopy result and informs patient M.gen test being taken.

BMS requests the M.gen test on NASH and adds comment "specimen sent for M.gen testing" in microscopy comments box on NASH



BMS ALSO add red sticker (WoSSVC Mycoplasma Testing) to any specimen bags where **recurrent** epididymo-orchitis is written in clinical details

(regardless of microscopy result).



Specimens for M.gen can then be added to Virus Laboratory specimen bag for onward transport to the Virus Laboratory, GRI using routine NHS driver uplifts.



Any M.gen requests that are inadvertently overlooked, details can be emailed to the Virus Laboratory on a daily basis to **west.ssvc2@nhs.scot**.

Flow Chart (ii) (for Sandyford Central)

FEMALE ANATOMY PATIENTS

Patients with PID requiring treatment

Collect vulvovaginal swab



Clinician informs patient M.gen test being taken



Clinician orders Ct, Gc and Mgen on Sunquest and sticks sunquest label to sample



Specimen taken to BOX C (**samples for M.gen testing**)
(Ground floor specimen collection room)



BOX C specimens are transferred to Sandyford laboratory M.gen tray



Specimens for M.gen can then be added to Virus Laboratory specimen bag for onward transport to the Virus Laboratory using routine NHS driver uplifts.



Any M.gen requests that are inadvertently overlooked, details can be emailed to the Virus Laboratory on a daily basis to **west.ssvc2@nhs.scot**.

Flow Chart (iii)

Female/ Male patients attending for:

M.gen TOC
M.gen contact

Patient may attend for a GRAB kit or may attend routine clinic



Collect vaginal swab, FVU or rectal swab and transfer to Abbott vial
(orange top)
(may be self-taken)



Clinician informs patient M.gen test being taken



Clinician orders Mgen on sunquest and sticks sunquest label to sample



Specimen taken to BOX A for checking



Specimens for M.gen can then be added to Virus Laboratory specimen
bag for onward transport to the Virus Laboratory using routine NHS driver
uplifts.

Seeing the Results:

Results including resistance are returned to the NaSH Results Reporting area from both the WoSSVC (primary result, Speedx ResistancePlus® MG) and the Scottish STI Bacterial Reference lab (sequencing data). The primary NAAT test will map into NaSH Test Special Forms and is communicated via Netcall results phone line.

You **must check Results Reporting** in the patient summary for the resistance information as this does not map into the NaSH test Special Form. **Please do not rely on the comments in the Test Result form which just describe the test.**

Please take care to read and interpret the resistance test result carefully. Seek help if unsure.

This example shows a positive result for *M. genitalium* which is susceptible to azithromycin.

Results Reporting

Department		
NASH		
Test Name	May 18, 2021 00:00	May 18, 2021 00:00
M. gen resistance [NaSH] ()	Azithromycin resist. NOT predicted	
M. genitalium [NaSH] ()	DETECTED by PCR	
C. trachomatis : [NaSH] ()		Not detected by PCR
N. gonorrhoeae : [NaSH] ()		Not detected by PCR
HIV antibody/antigen [NaSH] ()		
TP-syphilis antibody [NaSH] ()		
Ct Polymerase Chain Reaction [RVD] ()		
GC Polymerase Chain Reaction [RVD] ()		

This example is a result where doxycycline should be followed by moxifloxacin, after careful informed discussion.

Results Reporting

Department		
NASH		
Test Name	Jan 14, 2022 09:40	Jan 14, 2022 00:00
M. gen resistance [NaSH] ()	Azithromycin RESISTANCE predicted	
M. genitalium [NaSH] ()	DETECTED by PCR	
HIV antibody/antigen [NaSH] ()		Not detected
TP-syphilis antibody [NaSH] ()		Not detected
Routine Culture [MSGN] ()		

NaSH Results Reporting

Management:


Treatment – index case – *M genitalium*

Macrolide (e.g azithromycin) resistance in UK is estimated at around 33%. All positive *M genitalium* samples are tested for macrolide resistance-associated mutations (MRAM) using the SpeedX ResistancePlus® MG as part of the diagnostic test.

Doxycycline is used to lower bacterial load in suspected *M genitalium* (ie non-resolved non-gonococcal urethritis) pending final treatment choice, which is either multiday azithromycin or moxifloxacin (where there is confirmed macrolide resistance).

Patients found to have *M. genitalium* need **same-day clinical notes review, a prescription and recall** to collect the appropriate second antibiotic from the dispensing clinic. The sexual health adviser team will lead this process using the SC GUM Results Virtual list to request senior medical input in complicated cases or where fluoroquinolones are required

Patients who have fully clinically recovered after doxycycline can be offered the option to **defer further antibiotics and return to clinic if symptoms recur**. Patients should be advised to abstain for 14 days after start of treatment.



Taken from BASHH 2025 Guideline.

Figure 1 Suggested treatment pathway for men presenting with non-gonococcal urethritis who subsequently test positive for *Mycoplasma genitalium*:

Doxycycline 100 mg bd for 7 days then Azithromycin 3d should be started **within 2 weeks of finishing doxycycline** (Azithromycin 3d: azithromycin 1g, then 500 mg od for 2 days)

MRAM (macrolide resistance associated mutation): Doxycycline 100 mg bd for 7 days then Moxifloxacin should be started **within 2 weeks of finishing doxycycline** (Moxifloxacin 400mg od for 7 days)

The reference laboratory undertakes further sequencing to confirm the SpeeDx result and report on possible quinolone-associated resistance mutations. This is for information only and may be of use to consultants in constructing salvage regimens for those who do not improve with the standard treatment approach.

Treatment – Regimens:

***M. genitalium* positive – no macrolide resistance**

Doxycycline 100mg two times daily for 7 days
followed by
Azithromycin 1g orally as a single dose then 500mg orally once daily for 2 days

***M genitalium* positive – macrolide resistance predicted**

Doxycycline 100mg two times daily for 7 days
followed by
Moxifloxacin 400mg orally once daily for **SEVEN (7)** days (NB not in pregnancy)

Complicated infection (eg severe epididymo-orchitis or PID in M.gen contact or proven case)

Moxifloxacin 400mg orally once daily for 14 days (NB not in pregnancy)

Clinical failure of initial resistance-guided treatment :

Treatment failure is defined as persistent symptoms following treatment, or a positive test in the presence of symptoms taken 5 weeks post-treatment (if indicated)

A GUM consultant must decide on appropriate treatment regimen in all cases where this approach has failed. Example regimens may include

If treatment with azithromycin failed:

Doxycycline 100mg two times daily for 7 days
followed by
Moxifloxacin 400mg orally once daily for **SEVEN (7)** days (NB not in pregnancy)

If treatment with moxifloxacin failed:

Minocycline 100 mg orally bd for 14 days is preferred option
or
Doxycycline 100 mg bd for 7 days followed by **Pristinamycin*** 1000 mg orally three times daily for 14 days.

* see protocol at end for pristinamycin prescribing in this exceptional situation.

Rectal infection:

Should be managed in the same way as urethral infection. For severe proctitis in someone known to be in contact with *M genitalium*, a longer course of moxifloxacin (14 days) may be considered.

Pregnancy & Breast Feeding:

Please discuss with senior clinician. Patients may choose to delay treatment until after delivery.

- Azithromycin use during pregnancy is unlikely to increase the risk of birth defects or adverse pregnancy outcomes: 3 day azithromycin course can be used.
- Moxifloxacin is **contraindicated**.
- Doxycycline is considered safe for the use in the first trimester by FDA but BNF recommends against.

Breast feeding

- Low levels of azithromycin, and risk is considered low. Infant should be monitored for possible side effects due to effects on gastrointestinal flora, including diarrhoea and candidiasis. Doxycycline is excreted in milk and is contraindicated in breast feeding mothers.

HIV:

Treatment in people living with HIV is the same as above.

Adverse events:

Azithromycin, doxycycline, moxifloxacin, and pristinamycin can all cause gastro-intestinal intolerance such as nausea.

MHRA issued strengthened [guidance](#) in January 2024 that fluoroquinolones should only be used where other commonly used antibiotics are inappropriate due to serious, sometimes irreversible, musculoskeletal, neurological and psychiatric adverse effects including completed suicide. The BASHH response states: *. Clinicians are advised to prescribe fluoroquinolones only when judged to be the most appropriate treatment for the patient's infection after considering factors such as likely causative organisms, antimicrobial resistance factors, the availability of alternative agents, and pharmacological considerations such as tissue penetration.*

We recommend discussion about this is fully documented and decision making justified. In the case of *M. genitalium* there are no alternative licensed agents for macrolide-resistant infection and the MHRA guidance specifically mentions resistance to first-line antibiotics as a valid reason for use. .

We recommend discussing side effects using the [MHRA patient information leaflet](#) at https://assets.publishing.service.gov.uk/media/65aa9125c69eea0010883840/FQ_Patient_Information_Sheet_-_TO_PUBLISH.pdf and then sending the link by SMS to evidence the discussion

QT Prolongation: Certain medications including fluconazole, macrolide and fluoroquinolone antibiotics cause QT prolongation and should not be prescribed with interacting medications. This is unlikely to be of clinical significance for stat doses but is important for longer courses. Please use BNF Interaction Checker to ensure these medications are safe to prescribe for your patient and discuss with a senior colleague if necessary.

Partner notification and testing of sexual contacts

Test only **ongoing sexual partners**, including non-regular partners where there is likely to be further sexual contact. This is primarily to reduce the risk of re-infection to the index patient. There is no clear merit in 'look-backs'.

If the partner's test is positive, treat based on **their** resistance markers. If the partner's results are negative and infection risk was within last two weeks offer re-testing after a two-week window. This interval is not evidence-based but pragmatic. If they remain negative no further action is needed.

Epidemiological treatment, without results, has a high risk of treatment failure, and further antibiotic resistance. On rare occasions it may be necessary to treat ongoing partners prior to their own results being available. In this situation treat based on the index case's resistance prediction where available.

As a last resort where immediate treatment is needed (eg travel away, no resistance data available) ongoing partners should be tested and then treated with the same antibiotics as the index patient.

You must be able to justify your treatment choice and decisions especially using moxifloxacin.

General advice:

Patient Information Leaflets to be updated

Patients should be advised to abstain from sexual intercourse until they and their partner(s) have completed treatment or, in patients with PID, until 14 days after the start of treatment, and until symptoms have resolved.

Follow up:

Routine test of cure is no longer recommended.

All symptomatic patients should be added to SC SHA Virtual 5 weeks after start of treatment for a follow up phone call.

For individuals who remain symptomatic after treatment, once risk of re-infection and non-compliance with medication has been excluded, a TOC should be performed at least 5 weeks after the start of the treatment

For asymptomatic contacts, please advise them to abstain from sex until 2 weeks after start of secondary treatment and to contact the SHA office if they develop symptoms (as per Mgen indications on page 1).

People who do not respond to treatment should be managed by a consultant GUM physician, and reported.

References

Soni S, Fifer H, Al-Shakarchi Y et al. British Association of Sexual Health and HIV National guideline for the management of infection with *Mycoplasma genitalium*, 2025

https://www.bashh.org/resources/19/mycoplasma_genitalium_2025

[accessed 09 March 2026]

BASHH Clinical Effectiveness Group. Response to MHRA statement on the use of quinolone antimicrobials. Published 11/03/2024. Available at [Response to MHRA statement on the use of quinolone antimicrobials | BASHH](#) [accessed 09 March 2026]

Jensen J.S, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M et al. European guideline on the management of *Mycoplasma genitalium* infections. First published: 19 February 2022 <https://doi.org/10.1111/jdv.17972> [accessed 09 March 2026]

Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate. Available at <https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-must-now-only-be-prescribed-when-other-commonly-recommended-antibiotics-are-inappropriate> [accessed 09 March 2026]



Oral Pristinamycin use in the treatment of *Mycoplasma genitalium* infection in adults

